ATUM
Integrated biotechnology company offering gene design and synthesis, protein engineering and expression, cell line development, expression host platforms, reagent supply, and analytical services. Provides transposase-based genome integration, computational vector design, gRNA design and CRISPR cloning workflows, high-throughput expression and cloning processes, and LIMS and machine-learning tools to move projects from sequence design through research cell bank and GMP-ready processes.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Expression vectors for bacterial, mammalian and yeast hosts
Catalog vectors with a range of promoters, selection markers and elements for transient or stable expression and multi‑ORF constructs.
Transposon integration reagents and integration platform
Reagents and support to apply a transposase-mediated integration workflow for generating stable pools and clonal cell lines.
Pre-characterized transient expression host for discovery-scale production
CHO-derived transient expression host intended to produce discovery material with critical quality attributes aligned to CHO manufacturing hosts.
Characterized Pichia pastoris strains
Catalog yeast strains with genomic characterization and culture/induction protocols for fermentation and expression experiments.
Affinity tag proteases and validated cleavage protocols
Affinity-purified proteases and validated protocols for removal of fusion tags from recombinant proteins.
Pre-linearized CRISPR vectors and type IIS cloning kit
Pre-linearized CRISPR vector DNA and associated type IIS-based cloning reagents designed to enable rapid insertion of gRNA sequences via a short room-temperature cloning reaction.
Expression vectors for bacterial, mammalian and yeast hosts
Catalog vectors with a range of promoters, selection markers and elements for transient or stable expression and multi‑ORF constructs.
Transposon integration reagents and integration platform
Reagents and support to apply a transposase-mediated integration workflow for generating stable pools and clonal cell lines.
Pre-characterized transient expression host for discovery-scale production
CHO-derived transient expression host intended to produce discovery material with critical quality attributes aligned to CHO manufacturing hosts.
Characterized Pichia pastoris strains
Catalog yeast strains with genomic characterization and culture/induction protocols for fermentation and expression experiments.
Affinity tag proteases and validated cleavage protocols
Affinity-purified proteases and validated protocols for removal of fusion tags from recombinant proteins.
Pre-linearized CRISPR vectors and type IIS cloning kit
Pre-linearized CRISPR vector DNA and associated type IIS-based cloning reagents designed to enable rapid insertion of gRNA sequences via a short room-temperature cloning reaction.
Services
Design and synthesis of codon-optimized genes and constructs for multiple expression hosts, with support for vector cloning and sequence optimization.
Stable pool generation, clone isolation, stability testing and research/master cell bank creation using transposase-based integration.
Transient and stable mammalian protein production workflows for discovery to preclinical quantities, with preparative purification and analytics.
Antibody sequence optimization, developability assessment, and binding/kinetic assay development using SPR and BLI.
Web-based gRNA design combined with cloning services to deliver ready-to-transfect CRISPR vectors (including dual‑gRNA nickase constructs); includes guidance on primer design, avoidance of type IIS recognition sites, and sequencing-based screening workflows.
Catalog supply of proteases for tag cleavage and other reagents to support protein workflows.
Design and synthesis of codon-optimized genes and constructs for multiple expression hosts, with support for vector cloning and sequence optimization.
Stable pool generation, clone isolation, stability testing and research/master cell bank creation using transposase-based integration.
Transient and stable mammalian protein production workflows for discovery to preclinical quantities, with preparative purification and analytics.
Antibody sequence optimization, developability assessment, and binding/kinetic assay development using SPR and BLI.
Web-based gRNA design combined with cloning services to deliver ready-to-transfect CRISPR vectors (including dual‑gRNA nickase constructs); includes guidance on primer design, avoidance of type IIS recognition sites, and sequencing-based screening workflows.
Catalog supply of proteases for tag cleavage and other reagents to support protein workflows.
Expertise Areas
- Gene design and synthetic biology
- Cell line development and clonal selection
- Protein expression and purification
- Antibody engineering and developability assessment
Key Technologies
- Transposase-mediated genome integration
- Computational vector and promoter engineering
- Transient and stable mammalian expression
- gRNA specificity scoring algorithms
News & Updates
Participation and presentations at events including PEGS Europe, AACR, PEGS Boston and bispecific/PEACe conferences.
Licensing agreement providing access to a transposase-based integration platform to support engineered exosome-producing cell lines.
Patent licensing and collaboration to apply a transposase integration platform for rapid generation of high-producing cell lines.
Collaboration leveraging a transposase-based platform to develop cell lines for a virus-like particle vaccine candidate.
Temporary provision of protein production platform access to academic and commercial groups working on COVID-19 diagnostics and therapeutics.
EcoVadis Silver Medal recognition placing the company in a high percentile for sustainability within the scientific R&D industry.
Participation and presentations at events including PEGS Europe, AACR, PEGS Boston and bispecific/PEACe conferences.
Licensing agreement providing access to a transposase-based integration platform to support engineered exosome-producing cell lines.
Patent licensing and collaboration to apply a transposase integration platform for rapid generation of high-producing cell lines.
Collaboration leveraging a transposase-based platform to develop cell lines for a virus-like particle vaccine candidate.
Temporary provision of protein production platform access to academic and commercial groups working on COVID-19 diagnostics and therapeutics.
EcoVadis Silver Medal recognition placing the company in a high percentile for sustainability within the scientific R&D industry.